Modeling and simulation to support dose selection and clinical development of SC-75416, selective COX-2 inhibitor for the treatment of acute and chronic pain

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 857-866

  Kowalski, K G ^a   Olson, S ^a   Remmers, A E ^b   Hutmacher, M M ^a  

^a PFIZER INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; PLACEBO; ROFECOXIB; SC 75416; VALDECOXIB;

ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; HUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SIMULATION;

ACUTE DISEASE; BENZOPYRANS; CHRONIC DISEASE; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; PAIN;

EID: 43949143899     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100374     Document Type: Article

References (13)

1. Masferrer, J.L. et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonuclerogenic. Proc. Natl. Acad. Sci. USA 91, 3228-3232 (1994).
2. Seibert, K. et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91, 12013-12017 (1994).
3. Schnitzer, T.J. & Hochberg, M.C. COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 69 (suppl. 1), SI20-SI30 (2002).
4. Katz, N. Coxibs: evolving role in pain management. Semin. Arthritis Rheum. 32 (suppl. 1), 15-24 (2002).
5. Sheiner, L.B. A new approach to the analysis of analgesic trials, illustrated with bromfenac data. Clin. Pharmacol. Ther. 56, 309-322 (1994).
6. Mandema, J.W. & Stanski, D.R. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60, 619-635 (1996).
7. Sheiner, L.B., Beal, S.L. & Dunne, A. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J. Am. Stat. Assoc. 92, 1235-1244 (1997).
8. Malstrom, K., Sapre, A., Coughlin, H., Agrawal, N.G.B., Mazenko, R.S. & Fricke, J.R. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin. Ther. 26, 667-679 (2004).
9. Zelenakas, K., Fricke, J.R., Jayawardene, S. & Kellstein, D. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative post oral surgery pain. Int. J. Clin. Pract. 58, 251-266 (2004).
10. Fricke, J. et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am. J. Ther. 9, 89-97 (2002).
11. Beal, S.L., Sheiner, L.B. & Boeckmann, A.J. NONMEM. Users Guides (Icon Development Solutions, Ellicott City, MD, 1989-2006).
12. FDA. Rofecoxib summary basis of approval. Clinical Pharmacology and Biopharmaceutics Review 27 〈http://www.fda.gov/cder/foi/nda/99/ 021042_52_vioxx_clinphrmr_P2.pdf〉 (1999).
13. SAS Institute Inc. SAS/STAT. User's Guide, Version 8 (SAS Institute, Cary, NC, 1999).